ClinicalTrials.gg
RecruitingNCT07109219ALLightUpdated Nov 13, 2026

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

A Phase 1/2 interventional study of AZD4512 monotherapy in B-cell Acute Lymphoblastic Leukemia (B-ALL), sponsored by AstraZeneca. Recruiting at 27 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 15, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
83
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 725 studies in Burkitt Lymphoma with a site in United States — 71 open to participants now, 118 under way, 10 of them phase 3. Burkitt Lymphoma · United States.

Planned enrollment
119th of 594
83 · median 37
Started
2025
with 16 others
Phase 1/2
83 of 725
14 open now
Primary completion
2028-10
later than 84 of 117 live
Registered
706th of 725
by date

Among the 725 studies in Burkitt Lymphoma with a site in United States, this one is the 119th largest by planned enrollment of the 594 interventional ones that give a count, is one of 17 that started in 2025, is one of 83 in phase 1/2, reaches primary completion later than 84 of the 117 other live ones, and was the 706th registered.

Burkitt Lymphoma

977 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

71 of the 725 studies in Burkitt Lymphoma with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 71 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 42 (32%) set no upper age limit and 77 (58%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 725 studies in Burkitt Lymphoma with a site in United States, or all of them as a file.
02

Study summary

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).

Read the detailed description

In this Phase I/II, open-label multi-center study AZD4512 will be administered to adult/young adult patients (Module 1: >=16 years; Module 2: >=12 years) with relapsed/refractory B-Cell acute lymphoblastic leukemia (B-ALL). This study will have 2 parts: Module 1 - Dose Escalation and Module 2 - Dose Optimization.

03

Conditions studied

  • B-cell Acute Lymphoblastic Leukemia (B-ALL)

Keywords

  • Acute lymphoblastic leukemia (B-ALL)
  • Dose escalation
  • Dose optimization
  • Cluster of differentiation 22 (CD22)
  • Antibody-drug conjugate (ADC)
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age:

    • 16 years old in Module 1 (US only: ≥18year)
    • 12 years old in Module 2

      2. Diagnosis: Known Diagnosis of CD22-positive B-ALL based on criteria established by WHO (Alaggio et al. 2022).

  • All Participants must have B-ALL ('relapsed' defined as bone marrow blasts > 5% or reappearance of blasts in PB)
  • Module 1 (DE): R/R B-ALL [Ph(-) and Ph(+)]
  • Backfill of Module 1 and Module 2 (DO): R/R B-ALL [Ph(-)] with demonstration of CD22 expression by local assessment in screening.

    3. Performance status ( ≤ 2; ≥ 50; LPS ≥ 50)

    4. Peripheral lymphoblast count \< 10,000/µL (may receive cytoreduction prior to C1D1 per protocol-specified criteria)

    5. Prior therapies:

  • Module 1 (DE): At least 2 prior therapies with refractoriness or relapse, or 1 prior therapy with refractoriness or relapse and no standard options available. For Ph+ B-ALL: intolerant to or have to TKI therapy or R/R disease despite treatment with at least 2 prior TKIs or at least one 3rd generation TKI
  • Backfill of Module 1 (backfills) and Module 2 (DO): at least one (SOC or clinical trial) to which the participant has been either refractory or has subsequently relapsed.
  • Participants who have received prior CD22 targeted therapies and were not refractory to these therapies are eligible

    6. Prior DLI >4 weeks, prior cell therapy or >8 weeks, alloHSCT >12 weeks

Exclusion criteria

Exclusion Criteria:

  1. Burkitt lymphoma and leukemia
  2. Isolated extramedullary disease; Active testicular or CNS (> CNS1) involvement
  3. Unresolved non-heme toxicities Grade ≥ 2 (except alopecia, stable Grade ≤ 2 neuropathy, vitiligo, endocrine disorders controlled with therapy)
  4. History of drug-induced non-infectious ILD/pneumonitis requiring oral or IV or supplemental oxygen or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
  5. Prior/concomitant therapy

    • Cytotoxic treatment within 14 days (except ALL maintenance medications or cytoreduction)
    • Biologic (immuno-oncology) treatment within 28 days or 5 half-lives (whichever is shorter)
    • Non-CNS radiation within 2 weeks \& CNS radiation within 4 weeks
    • Medications known to prolong and/or associated with Torsades de Pointes within 5 half-lives
    • Strong inhibitors of CYP 3A4 within 14 days or 5 half-lives (whichever is longer)
    • agents or study interventions in the last 30 days or 5 half-lives prior to the first dose of AZD4512 whichever is longer.

If the investigational product is an agent to treat B-ALL and meets the modality criteria, then a specific must be adhered to instead.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
83 participants (estimated)

Study arms

  • Experimental
    Module 1 Dose Escalation

    Module 1 will evaluate escalating doses of AZD4512 as monotherapy to determine the maximum tolerated dose (MTD) and/or doses of AZD4512 for subsequent evaluation in Module 2 (dose optimization), in participants with relapsed/refractory (R/R) Philadelphia chromosome positive (Ph\[+\]) and negative (Ph\[-\]) B-ALL, R/R as defined by National Comprehensive Cancer Network (NCCN) guidelines.

    Combination Product: AZD4512 monotherapy

  • Experimental
    Module 2 Dose Optimization

    Module 2 will randomize participants with R/R (as defined by NCCN guidelines) Ph(-) BALL only across 2 to 3 dose levels identified in Module 1 to receive AZD4512 monotherapy for further exploration of the doses. The aim of Module 2 is to identify the recommended Phase 2 dose (RP2D) of AZD4512 monotherapy, evaluate the efficacy and further define the safety profile of AZD4512.

    Combination Product: AZD4512 monotherapy

Interventions

  • Combination productAZD4512 monotherapy

    Patients will receive AZD4512 as monotherapy via intravenous infusion. AZD4512 is an antibody-drug conjugate targeting CD22

06

What researchers measure

Primary outcomes

  1. Module 1 (Dose Escalation): Number of participants with dose-limiting toxicities (DLTs).

    DLTs are dose-limiting toxicities as defined in the study protocol.

    Time frame: From first dose up to 21 days (DLT period).

  2. Module 1 (Dose Escalation): Frequency, duration and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs)

    Assessed by the CTCAE criteria version 5.0

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  3. Module 1 (Dose Escalation): Frequency of dose interruptions, modifications, delays, and discontinuations due to AEs

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  4. Module 1 (Dose Escalation): Number of participants with clinically significant changes in laboratory values, ECGs, performance status, and vital signs

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  5. Module 2 (Dose Optimization): Overall response rate (ORR) in participants with R/R Ph(-) B-ALL

    To evaluate the efficacy based on NCCN response criteria, measured by ORR (CR/CRh)

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  6. Module 2 (Dose Optimization): Frequency, duration and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs)

    Assessed by the CTCAE criteria version 5.0

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  7. Module 2 (Dose Optimization): Frequency of dose interruptions, modifications, delays, and discontinuations due to AEs

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  8. Module 2 (Dose Optimization): Number of participants with clinically significant changes in laboratory values, ECGs, performance status, and vital signs

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

Secondary outcomes

  1. Module 1 (Dose Escalation): Plasma PK parameters of AZD4512

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  2. Module 1 (Dose Escalation): Total antibody and total unconjugated payload

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  3. Module 1 (Dose Escalation): Area Under Curve (AUC)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  4. Module 1 (Dose Escalation): Peak Plasma Concentration (Cmax)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  5. Module 1 (Dose Escalation): Time to max concentration (Tmax)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  6. Module 1 (Dose Escalation): Half life (T1/2)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  7. Module 1 (Dose Escalation): Clearance (CL)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  8. Module 1 (Dose Escalation): Volume of distribution (Vz)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  9. Module 1 (Dose Escalation): Number and percentage of participants who develop anti-drug antibodies (ADAs)

    To determine the immunogenicity of AZD4512 as monotherapy in participants with R/R B-ALL.

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  10. Module 1 (Dose Escalation): Objective Response Rate (ORR): proportion of participants with CR or CRh

    To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  11. Module 1 (Dose Escalation): Composite Complete Remission (CRc) rate: proportion of participants with CR, CRh, or CRi

    To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  12. Module 1 (Dose Escalation): Complete Remission (CR) rate

    To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  13. Module 1 (Dose Escalation): Time to Response (TTR)

    To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  14. Module 1 (Dose Escalation): Duration of Response (DoR)

    \- To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  15. Module 1 (Dose Escalation): Event-Free Survival (EFS)

    \- To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  16. Module 1 (Dose Escalation): Overall Survival (OS)

    \- To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  17. Module 1 (Dose Escalation): Percentage of participants who receive subsequent allogeneic hematopoietic stem cell transplant (HSCT)

    \- To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  18. Module 2 (Dose Optimization): Complete Remission (CR) rate

    To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  19. Module 2 (Dose Optimization):Composite Complete Remission (CRc) rate: proportion of participants with CR, CRh, or CRi

    To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  20. Module 2 (Dose Optimization):Time to Response (TTR)

    To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  21. Module 2 (Dose Optimization): Duration of Response (DoR)

    To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  22. Module 2 (Dose Optimization):Event-Free Survival (EFS)

    To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  23. Module 2 (Dose Optimization): Overall Survival (OS)

    To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  24. Module 2 (Dose Optimization): Percentage of participants who receive subsequent allogeneic hematopoietic stem cell transplant (HSCT)

    To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  25. Module 2 (Dose Optimization): MRD-negative CR rate, CR/CRh (ORR), CR/CRi/CRh (CRc) rate

    To evaluate the impact of AZD4512 on MRD as assessed by NGS (central)

    Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months

  26. Module 2 (Dose Optimization): Plasma PK parameters of AZD4512

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  27. Module 2 (Dose Optimization): total antibody and total unconjugated payload

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  28. Module 2 (Dose Optimization): Area Under Curve (AUC)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  29. Module 2 (Dose Optimzation): Peak Plasma Concentration (Cmax)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  30. Module 2 (Dose Optimization): Time to max concentration (Tmax)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  31. Module 2 (Dose Optimization): Half life (T1/2)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  32. Module 2 (Dose Optimization): Clearance (CL)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  33. Module 2 (Dose Optimization): Volume of distribution (Vz)

    To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

  34. Module 2 (Dose Optimization): Summary of of pre-existing and treatment induced ADAs for AZD4512 (positive or negative, titers)

    To determine the immunogenicity of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]

    Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)

07

Study locations

21 of 27 sites recruiting
  • Research Site
    Duarte, California 91010, United States
    Recruiting
  • Research Site
    Jacksonville, Florida 32224, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Chicago, Illinois 60611, United States
    Recruiting
  • Research Site
    Iowa City, Iowa 52242, United States
    Recruiting
  • Research Site
    Franklin, Tennessee 37067, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
    Not yet recruiting
  • Research Site
    Toronto, Ontario M5G 1X6, Canada
    Recruiting
  • Research Site
    Guangzhou, 510515, China
    Not yet recruiting
  • Research Site
    Tianjin, 301600, China
    Not yet recruiting
  • Research Site
    Bunkyō City, 113-8677, Japan
    Recruiting
  • Research Site
    Chūōku, 104-0045, Japan
    Recruiting
  • Research Site
    Kashiwa, 277-8577, Japan
    Not yet recruiting
  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Seoul, 06351, South Korea
    Recruiting
  • Research Site
    Seoul, 06591, South Korea
    Recruiting
  • Research Site
    Seoul, 3722, South Korea
    Recruiting
  • Research Site
    Badalona, 8916, Spain
    Recruiting
  • Research Site
    Barcelona, 08035, Spain
    Recruiting
  • Research Site
    Salamanca, 37007, Spain
    Recruiting
  • Research Site
    Santander, 39008, Spain
    Recruiting
  • Research Site
    Valencia, 46026, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Taichung, 40705, Taiwan
    Recruiting
  • Research Site
    Taipei, 106, Taiwan
    Recruiting
  • Research Site
    Bloomsbury, W1T 7HA, United Kingdom
    Recruiting
  • Research Site
    Manchester, M20 4BX, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2028, 34 months after the start.

Of 50 phase 1/2 interventional studies under Burkitt Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 114. This study's planned 34 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Apr 2028 → Oct 2028 and completion Jul 2028 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Aug 7, 2025
StartActual
Nov 12, 2025
Primary completionEst.
Oct 11, 2028was Apr 2028
CompletionEst.
Jul 18, 2029was Jul 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 Japan, 1 Spain)
  • Research Site · Kashiwa, Japan
  • Research Site · Badalona, Spain
Show 1 removed
  • Research Site · Badalona(Barcelona), Spain
Oct 15, 2026
Primary completion
Apr 28, 2028→Oct 11, 2028
Oct 15, 2026
Study completion
Jul 3, 2028→Jul 18, 2029
Oct 15, 2026
Eligibility
4 inclusion criteria edited, 3 added, 1 removed; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedAll Participants must have relapsed or refractory B-ALL ('relapsed' defined as bone marrow blasts > 5% or reappearance of blasts in PB)
  • EditedModule 1 (DE): R/R B-ALL [Ph(-) B-ALL and Ph(+) B-ALL - R/R]
  • EditedBackfill of Module 1 and Module 2 (DO): R/R B-ALL [Ph(-) B-ALL] with demonstration of CD22 expression by local assessment in screening.
  • Removed5. At least 2 prior therapies with refractoriness or relapse, or 1 prior therapy with refractoriness or relapse and no standard options available. Participants who have received prior CD22 targeted therapies are eligible.
  • Added5. Prior therapies:
  • EditedModule 1 (DE): At least 2 prior therapies with refractoriness or relapse, or 1 prior therapy with refractoriness or relapse and no standard options available. For Ph+ B-ALL (Module 1 DE only): intolerant to or have contraindications to TKI therapy or R/R disease despite treatment with at least 2 prior TKIs or at least one 3rd generation TKI
  • AddedBackfill of Module 1 (backfills) and Module 2 (DO): at least one prior line of therapy (SOC or clinical trial) to which the participant has been either refractory or has subsequently relapsed.
  • AddedParticipants who have received prior CD22 targeted therapies and were not refractory to these therapies are eligible
Exclusion criteria
  • AddedInvestigational agents or study interventions in the last 30 days or 5 half-lives prior to the first dose of AZD4512 whichever is longer.
  • EditedInvestigational agents or study interventions in the last 30 days or 5 half-lives prior to the first dose of AZD4512 whichever is longer. If the investigational product is an agent to treat B-ALL and meets the modality criteria, then a specific washout period must be adhered to instead.
Oct 15, 2026
Primary outcomes
6 time frame changed
What changed in the outcomes
  • Time frameModule 1 (Dose Escalation): Frequency, duration and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 1 (Dose Escalation): Frequency of dose interruptions, modifications, delays, and discontinuations due to AEsFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 1 (Dose Escalation): Number of participants with clinically significant changes in laboratory values, ECGs, performance status, and vital signsFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimization): Frequency, duration and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimization): Frequency of dose interruptions, modifications, delays, and discontinuations due to AEsFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimization): Number of participants with clinically significant changes in laboratory values, ECGs, performance status, and vital signsFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Oct 15, 2026
Secondary outcomes
18 time frame changed
What changed in the outcomes
  • Time frameModule 1 (Dose Escalation): Plasma PK parameters of AZD4512From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 1 (Dose Escalation): Total antibody and total unconjugated payloadFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 1 (Dose Escalation): Area Under Curve (AUC)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 1 (Dose Escalation): Peak Plasma Concentration (Cmax)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 1 (Dose Escalation): Time to max concentration (Tmax)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 1 (Dose Escalation): Half life (T1/2)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 1 (Dose Escalation): Clearance (CL)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 1 (Dose Escalation): Volume of distribution (Vz)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 1 (Dose Escalation): Number and percentage of participants who develop anti-drug antibodies (ADAs)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimization): Plasma PK parameters of AZD4512From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimization): total antibody and total unconjugated payloadFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimization): Area Under Curve (AUC)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimzation): Peak Plasma Concentration (Cmax)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimization): Time to max concentration (Tmax)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimization): Half life (T1/2)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimization): Clearance (CL)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimization): Volume of distribution (Vz)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
  • Time frameModule 2 (Dose Optimization): Summary of of pre-existing and treatment induced ADAs for AZD4512 (positive or negative, titers)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Oct 15, 2026
Show all 2 updates
  1. Nov 13, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Oct 15, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Japan, 1 Spain)
    • Research Site · Kashiwa, Japan
    • Research Site · Badalona, Spain
    Show 1 removed
    • Research Site · Badalona(Barcelona), Spain
    Primary completion Apr 28, 2028→Oct 11, 2028
    Study completion Jul 3, 2028→Jul 18, 2029
    Eligibility 4 inclusion criteria edited, 3 added, 1 removed; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedAll Participants must have relapsed or refractory B-ALL ('relapsed' defined as bone marrow blasts > 5% or reappearance of blasts in PB)
    • EditedModule 1 (DE): R/R B-ALL [Ph(-) B-ALL and Ph(+) B-ALL - R/R]
    • EditedBackfill of Module 1 and Module 2 (DO): R/R B-ALL [Ph(-) B-ALL] with demonstration of CD22 expression by local assessment in screening.
    • Removed5. At least 2 prior therapies with refractoriness or relapse, or 1 prior therapy with refractoriness or relapse and no standard options available. Participants who have received prior CD22 targeted therapies are eligible.
    • Added5. Prior therapies:
    • EditedModule 1 (DE): At least 2 prior therapies with refractoriness or relapse, or 1 prior therapy with refractoriness or relapse and no standard options available. For Ph+ B-ALL (Module 1 DE only): intolerant to or have contraindications to TKI therapy or R/R disease despite treatment with at least 2 prior TKIs or at least one 3rd generation TKI
    • AddedBackfill of Module 1 (backfills) and Module 2 (DO): at least one prior line of therapy (SOC or clinical trial) to which the participant has been either refractory or has subsequently relapsed.
    • AddedParticipants who have received prior CD22 targeted therapies and were not refractory to these therapies are eligible
    Exclusion criteria
    • AddedInvestigational agents or study interventions in the last 30 days or 5 half-lives prior to the first dose of AZD4512 whichever is longer.
    • EditedInvestigational agents or study interventions in the last 30 days or 5 half-lives prior to the first dose of AZD4512 whichever is longer. If the investigational product is an agent to treat B-ALL and meets the modality criteria, then a specific washout period must be adhered to instead.
    Primary outcomes 6 time frame changed
    What changed in the outcomes
    • Time frameModule 1 (Dose Escalation): Frequency, duration and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 1 (Dose Escalation): Frequency of dose interruptions, modifications, delays, and discontinuations due to AEsFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 1 (Dose Escalation): Number of participants with clinically significant changes in laboratory values, ECGs, performance status, and vital signsFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimization): Frequency, duration and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimization): Frequency of dose interruptions, modifications, delays, and discontinuations due to AEsFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimization): Number of participants with clinically significant changes in laboratory values, ECGs, performance status, and vital signsFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    Secondary outcomes 18 time frame changed
    What changed in the outcomes
    • Time frameModule 1 (Dose Escalation): Plasma PK parameters of AZD4512From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 1 (Dose Escalation): Total antibody and total unconjugated payloadFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 1 (Dose Escalation): Area Under Curve (AUC)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 1 (Dose Escalation): Peak Plasma Concentration (Cmax)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 1 (Dose Escalation): Time to max concentration (Tmax)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 1 (Dose Escalation): Half life (T1/2)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 1 (Dose Escalation): Clearance (CL)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 1 (Dose Escalation): Volume of distribution (Vz)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 1 (Dose Escalation): Number and percentage of participants who develop anti-drug antibodies (ADAs)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimization): Plasma PK parameters of AZD4512From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimization): total antibody and total unconjugated payloadFrom date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimization): Area Under Curve (AUC)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimzation): Peak Plasma Concentration (Cmax)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimization): Time to max concentration (Tmax)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimization): Half life (T1/2)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimization): Clearance (CL)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimization): Volume of distribution (Vz)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    • Time frameModule 2 (Dose Optimization): Summary of of pre-existing and treatment induced ADAs for AZD4512 (positive or negative, titers)From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months) → From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07109219
Lead sponsor
AstraZeneca
Collaborators
Fortrea
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Nov 12, 2025
Primary completion
Oct 11, 2028 (estimated)
Completion
Jul 18, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion